Skip to main content
. 2019 Aug 4;8(8):1170. doi: 10.3390/jcm8081170

Table 2.

Efficacy and safety gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer in the Japanese phase I/II trial.

Ueno (2016) [11]
N 34
Objective response rate 58.8%
Disease control rate 94.1%
Median PFS 6.5 months
Median OS 13.5 months
Common toxicities (Grade 3/4)
Neutropenia 70.6%
Febrile neutropenia 5.9%
Thrombocytopenia 14.7%
Fatigue -
Diarrhea 5.9%
Peripheral neuropathy 11.8%

PFS, Progression-free survival; OS, overall survival.